JP2018508532A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018508532A5 JP2018508532A5 JP2017546702A JP2017546702A JP2018508532A5 JP 2018508532 A5 JP2018508532 A5 JP 2018508532A5 JP 2017546702 A JP2017546702 A JP 2017546702A JP 2017546702 A JP2017546702 A JP 2017546702A JP 2018508532 A5 JP2018508532 A5 JP 2018508532A5
- Authority
- JP
- Japan
- Prior art keywords
- polr2a
- gene
- loss
- expression
- hemizygosity
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 101150025390 POLR2A gene Proteins 0.000 claims description 52
- 206010028980 Neoplasm Diseases 0.000 claims description 48
- 201000011510 cancer Diseases 0.000 claims description 41
- 238000000034 method Methods 0.000 claims description 36
- 102100021429 DNA-directed RNA polymerase II subunit RPB1 Human genes 0.000 claims description 29
- 101001106401 Homo sapiens DNA-directed RNA polymerase II subunit RPB1 Proteins 0.000 claims description 29
- 239000003112 inhibitor Substances 0.000 claims description 25
- 101150080074 TP53 gene Proteins 0.000 claims description 23
- 108700025694 p53 Genes Proteins 0.000 claims description 23
- WVHGJJRMKGDTEC-WCIJHFMNSA-N 2-[(1R,4S,8R,10S,13S,16S,27R,34S)-34-[(2S)-butan-2-yl]-8,22-dihydroxy-13-[(2R,3S)-3-hydroxybutan-2-yl]-2,5,11,14,27,30,33,36,39-nonaoxo-27lambda4-thia-3,6,12,15,25,29,32,35,38-nonazapentacyclo[14.12.11.06,10.018,26.019,24]nonatriaconta-18(26),19(24),20,22-tetraen-4-yl]acetamide Chemical compound CC[C@H](C)[C@@H]1NC(=O)CNC(=O)[C@@H]2Cc3c([nH]c4cc(O)ccc34)[S@](=O)C[C@H](NC(=O)CNC1=O)C(=O)N[C@@H](CC(N)=O)C(=O)N1C[C@H](O)C[C@H]1C(=O)N[C@@H]([C@@H](C)[C@H](C)O)C(=O)N2 WVHGJJRMKGDTEC-WCIJHFMNSA-N 0.000 claims description 11
- 231100000729 Amatoxin Toxicity 0.000 claims description 11
- 108010014709 amatoxin Proteins 0.000 claims description 11
- 238000000338 in vitro Methods 0.000 claims description 8
- 238000011282 treatment Methods 0.000 claims description 8
- 108090000623 proteins and genes Proteins 0.000 claims description 7
- 238000011529 RT qPCR Methods 0.000 claims description 6
- 239000000427 antigen Substances 0.000 claims description 6
- 102000036639 antigens Human genes 0.000 claims description 6
- 108091007433 antigens Proteins 0.000 claims description 6
- 239000002246 antineoplastic agent Substances 0.000 claims description 6
- 238000003556 assay Methods 0.000 claims description 6
- 230000003247 decreasing effect Effects 0.000 claims description 6
- 238000009396 hybridization Methods 0.000 claims description 5
- 108020004999 messenger RNA Proteins 0.000 claims description 5
- 238000011319 anticancer therapy Methods 0.000 claims description 4
- 102000004169 proteins and genes Human genes 0.000 claims description 4
- 238000002560 therapeutic procedure Methods 0.000 claims description 4
- 108091032973 (ribonucleotides)n+m Proteins 0.000 claims description 3
- FJHBVJOVLFPMQE-QFIPXVFZSA-N 7-Ethyl-10-Hydroxy-Camptothecin Chemical compound C1=C(O)C=C2C(CC)=C(CN3C(C4=C([C@@](C(=O)OC4)(O)CC)C=C33)=O)C3=NC2=C1 FJHBVJOVLFPMQE-QFIPXVFZSA-N 0.000 claims description 3
- 238000002965 ELISA Methods 0.000 claims description 3
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 claims description 3
- 238000000636 Northern blotting Methods 0.000 claims description 3
- 101710163270 Nuclease Proteins 0.000 claims description 3
- 229940127089 cytotoxic agent Drugs 0.000 claims description 3
- 229960002949 fluorouracil Drugs 0.000 claims description 3
- 238000004949 mass spectrometry Methods 0.000 claims description 3
- DWAFYCQODLXJNR-BNTLRKBRSA-L oxaliplatin Chemical compound O1C(=O)C(=O)O[Pt]11N[C@@H]2CCCC[C@H]2N1 DWAFYCQODLXJNR-BNTLRKBRSA-L 0.000 claims description 3
- 229960001756 oxaliplatin Drugs 0.000 claims description 3
- 238000003127 radioimmunoassay Methods 0.000 claims description 3
- 238000010839 reverse transcription Methods 0.000 claims description 3
- 229940124597 therapeutic agent Drugs 0.000 claims description 3
- 238000011222 transcriptome analysis Methods 0.000 claims description 3
- 238000001262 western blot Methods 0.000 claims description 3
- 208000003174 Brain Neoplasms Diseases 0.000 claims description 2
- 206010006187 Breast cancer Diseases 0.000 claims description 2
- 208000026310 Breast neoplasm Diseases 0.000 claims description 2
- 206010009944 Colon cancer Diseases 0.000 claims description 2
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims description 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 2
- 206010033128 Ovarian cancer Diseases 0.000 claims description 2
- 206010061535 Ovarian neoplasm Diseases 0.000 claims description 2
- 238000010222 PCR analysis Methods 0.000 claims description 2
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 2
- 206010060862 Prostate cancer Diseases 0.000 claims description 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 2
- 238000004458 analytical method Methods 0.000 claims description 2
- 239000003795 chemical substances by application Substances 0.000 claims description 2
- 239000003814 drug Substances 0.000 claims description 2
- 238000002651 drug therapy Methods 0.000 claims description 2
- 239000012634 fragment Substances 0.000 claims description 2
- 238000001114 immunoprecipitation Methods 0.000 claims description 2
- 201000007270 liver cancer Diseases 0.000 claims description 2
- 208000014018 liver neoplasm Diseases 0.000 claims description 2
- 201000005202 lung cancer Diseases 0.000 claims description 2
- 208000020816 lung neoplasm Diseases 0.000 claims description 2
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims description 2
- 230000001394 metastastic effect Effects 0.000 claims description 2
- 206010061289 metastatic neoplasm Diseases 0.000 claims description 2
- 108020004707 nucleic acids Proteins 0.000 claims description 2
- 102000039446 nucleic acids Human genes 0.000 claims description 2
- 150000007523 nucleic acids Chemical class 0.000 claims description 2
- 201000002528 pancreatic cancer Diseases 0.000 claims description 2
- 208000008443 pancreatic carcinoma Diseases 0.000 claims description 2
- 230000000306 recurrent effect Effects 0.000 claims description 2
- 102000015098 Tumor Suppressor Protein p53 Human genes 0.000 claims 2
- 108010078814 Tumor Suppressor Protein p53 Proteins 0.000 claims 2
- 238000003364 immunohistochemistry Methods 0.000 claims 2
- 101710098119 Chaperonin GroEL 2 Proteins 0.000 claims 1
- 108020004711 Nucleic Acid Probes Proteins 0.000 claims 1
- 238000002649 immunization Methods 0.000 claims 1
- 230000003053 immunization Effects 0.000 claims 1
- 239000002853 nucleic acid probe Substances 0.000 claims 1
- 238000001556 precipitation Methods 0.000 claims 1
- 238000002512 chemotherapy Methods 0.000 description 2
- 101800002638 Alpha-amanitin Proteins 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- RXGJTYFDKOHJHK-UHFFFAOYSA-N S-deoxo-amaninamide Natural products CCC(C)C1NC(=O)CNC(=O)C2Cc3c(SCC(NC(=O)CNC1=O)C(=O)NC(CC(=O)N)C(=O)N4CC(O)CC4C(=O)NC(C(C)C(O)CO)C(=O)N2)[nH]c5ccccc35 RXGJTYFDKOHJHK-UHFFFAOYSA-N 0.000 description 1
- 239000004007 alpha amanitin Substances 0.000 description 1
- CIORWBWIBBPXCG-SXZCQOKQSA-N alpha-amanitin Chemical compound O=C1N[C@@H](CC(N)=O)C(=O)N2C[C@H](O)C[C@H]2C(=O)N[C@@H]([C@@H](C)[C@@H](O)CO)C(=O)N[C@@H](C2)C(=O)NCC(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@H]1C[S@@](=O)C1=C2C2=CC=C(O)C=C2N1 CIORWBWIBBPXCG-SXZCQOKQSA-N 0.000 description 1
- CIORWBWIBBPXCG-UHFFFAOYSA-N alpha-amanitin Natural products O=C1NC(CC(N)=O)C(=O)N2CC(O)CC2C(=O)NC(C(C)C(O)CO)C(=O)NC(C2)C(=O)NCC(=O)NC(C(C)CC)C(=O)NCC(=O)NC1CS(=O)C1=C2C2=CC=C(O)C=C2N1 CIORWBWIBBPXCG-UHFFFAOYSA-N 0.000 description 1
- 238000000315 cryotherapy Methods 0.000 description 1
- 238000001794 hormone therapy Methods 0.000 description 1
- 230000002055 immunohistochemical effect Effects 0.000 description 1
- 238000009169 immunotherapy Methods 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 229960005502 α-amanitin Drugs 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562128480P | 2015-03-04 | 2015-03-04 | |
| US62/128,480 | 2015-03-04 | ||
| PCT/US2016/020687 WO2016141185A1 (en) | 2015-03-04 | 2016-03-03 | Methods of treating cancer harboring hemizygous loss of tp53 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020180195A Division JP7090933B2 (ja) | 2015-03-04 | 2020-10-28 | Ｔｐ５３のヘミ接合性喪失を保有するがんを処置する方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018508532A JP2018508532A (ja) | 2018-03-29 |
| JP2018508532A5 true JP2018508532A5 (enExample) | 2019-03-14 |
| JP6811718B2 JP6811718B2 (ja) | 2021-01-13 |
Family
ID=55586424
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017546702A Active JP6811718B2 (ja) | 2015-03-04 | 2016-03-03 | Ｔｐ５３のヘミ接合性喪失を保有するがんを処置する方法 |
| JP2020180195A Active JP7090933B2 (ja) | 2015-03-04 | 2020-10-28 | Ｔｐ５３のヘミ接合性喪失を保有するがんを処置する方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020180195A Active JP7090933B2 (ja) | 2015-03-04 | 2020-10-28 | Ｔｐ５３のヘミ接合性喪失を保有するがんを処置する方法 |
Country Status (24)
| Country | Link |
|---|---|
| US (2) | US10563204B2 (enExample) |
| EP (2) | EP3741855A1 (enExample) |
| JP (2) | JP6811718B2 (enExample) |
| KR (1) | KR102697493B1 (enExample) |
| CN (1) | CN107847553A (enExample) |
| AU (1) | AU2016226133B2 (enExample) |
| BR (1) | BR112017018861A2 (enExample) |
| CA (1) | CA2978632C (enExample) |
| CY (1) | CY1123489T1 (enExample) |
| DK (1) | DK3265565T3 (enExample) |
| ES (1) | ES2831157T3 (enExample) |
| HR (1) | HRP20201791T1 (enExample) |
| HU (1) | HUE051776T2 (enExample) |
| IL (2) | IL284264B (enExample) |
| LT (1) | LT3265565T (enExample) |
| MX (1) | MX379585B (enExample) |
| PL (1) | PL3265565T3 (enExample) |
| PT (1) | PT3265565T (enExample) |
| RS (1) | RS61047B1 (enExample) |
| RU (1) | RU2721953C2 (enExample) |
| SG (2) | SG11201707097RA (enExample) |
| SI (1) | SI3265565T1 (enExample) |
| WO (1) | WO2016141185A1 (enExample) |
| ZA (1) | ZA201706459B (enExample) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK3265565T3 (da) | 2015-03-04 | 2020-11-09 | Univ Texas | Fremgangsmåder til behandling af cancer, som har hemizygot tab af tp53 |
| US10111966B2 (en) | 2016-06-17 | 2018-10-30 | Magenta Therapeutics, Inc. | Methods for the depletion of CD117+ cells |
| US10576161B2 (en) | 2017-01-20 | 2020-03-03 | Magenta Therapeutics, Inc. | Compositions and methods for the depletion of CD137+ cells |
| EP3873541A4 (en) * | 2018-10-30 | 2022-08-31 | Ohio State Innovation Foundation | PH-ACTIVATED NANOPARTICLES |
| EP3917572A4 (en) | 2019-02-01 | 2022-11-09 | Board of Regents, The University of Texas System | MONOCLONAL ANTIBODIES AGAINST HUMAN MHC-RELATED DICKKOPF-1 PEPTIDES AND THEIR USES |
| CN111569076B (zh) * | 2020-06-28 | 2022-05-17 | 中国农业科学院特产研究所 | Polr2a抑制剂在制备药物中的应用 |
| CN114875107B (zh) * | 2021-05-19 | 2025-05-27 | 中南大学 | Polr2a作为治疗肿瘤疗效的生物标志物 |
| CN113702648B (zh) * | 2021-09-13 | 2024-06-04 | 中南大学湘雅三医院 | Polr2a在作为预测抗肿瘤药物的抗肿瘤疗效的生物标志物上的应用 |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5091513A (en) | 1987-05-21 | 1992-02-25 | Creative Biomolecules, Inc. | Biosynthetic antibody binding sites |
| US5824311A (en) | 1987-11-30 | 1998-10-20 | Trustees Of The University Of Pennsylvania | Treatment of tumors with monoclonal antibodies against oncogene antigens |
| US4870287A (en) | 1988-03-03 | 1989-09-26 | Loma Linda University Medical Center | Multi-station proton beam therapy system |
| US5846945A (en) | 1993-02-16 | 1998-12-08 | Onyx Pharmaceuticals, Inc. | Cytopathic viruses for therapy and prophylaxis of neoplasia |
| US5801005A (en) | 1993-03-17 | 1998-09-01 | University Of Washington | Immune reactivity to HER-2/neu protein for diagnosis of malignancies in which the HER-2/neu oncogene is associated |
| GB9506466D0 (en) | 1994-08-26 | 1995-05-17 | Prolifix Ltd | Cell cycle regulated repressor and dna element |
| US5760395A (en) | 1996-04-18 | 1998-06-02 | Universities Research Assoc., Inc. | Method and apparatus for laser-controlled proton beam radiology |
| US5739169A (en) | 1996-05-31 | 1998-04-14 | Procept, Incorporated | Aromatic compounds for inhibiting immune response |
| US20020064528A1 (en) | 2000-01-28 | 2002-05-30 | Zhenping Zhu | Antibodies specific to KDR and uses thereof |
| US20070207158A1 (en) | 2003-06-17 | 2007-09-06 | Harrison Roger G | Conjugate for the specific targeting of anticancer agents to tumor cells or tumor vasculature and production thereof |
| JP5518062B2 (ja) * | 2008-07-24 | 2014-06-11 | ネルビアーノ・メデイカル・サイエンシーズ・エツセ・エルレ・エルレ | オーロラキナーゼ阻害剤および抗悪性腫瘍剤を含む治療用組み合わせ |
| EP2416805B1 (en) * | 2009-04-08 | 2013-07-24 | Heinz Dr. Faulstich | Amatoxin antibody conjugates for the treatment of cancer |
| EP2497499A1 (en) | 2011-03-10 | 2012-09-12 | Heidelberg Pharma GmbH | Amatoxin-conjugates with improved linkages |
| EP2774624A1 (en) * | 2013-03-04 | 2014-09-10 | Heidelberg Pharma GmbH | Amatoxin derivatives |
| WO2016071856A1 (en) * | 2014-11-06 | 2016-05-12 | Novartis Ag | Amatoxin derivatives and conjugates thereof as inhibitors of rna polymerase |
| DK3265565T3 (da) | 2015-03-04 | 2020-11-09 | Univ Texas | Fremgangsmåder til behandling af cancer, som har hemizygot tab af tp53 |
-
2016
- 2016-03-03 DK DK16710890.1T patent/DK3265565T3/da active
- 2016-03-03 RU RU2017134347A patent/RU2721953C2/ru active
- 2016-03-03 HU HUE16710890A patent/HUE051776T2/hu unknown
- 2016-03-03 SI SI201630971T patent/SI3265565T1/sl unknown
- 2016-03-03 BR BR112017018861-9A patent/BR112017018861A2/pt not_active Application Discontinuation
- 2016-03-03 ES ES16710890T patent/ES2831157T3/es active Active
- 2016-03-03 SG SG11201707097RA patent/SG11201707097RA/en unknown
- 2016-03-03 PL PL16710890T patent/PL3265565T3/pl unknown
- 2016-03-03 PT PT167108901T patent/PT3265565T/pt unknown
- 2016-03-03 AU AU2016226133A patent/AU2016226133B2/en active Active
- 2016-03-03 WO PCT/US2016/020687 patent/WO2016141185A1/en not_active Ceased
- 2016-03-03 LT LTEP16710890.1T patent/LT3265565T/lt unknown
- 2016-03-03 US US15/555,411 patent/US10563204B2/en active Active
- 2016-03-03 SG SG10201907746TA patent/SG10201907746TA/en unknown
- 2016-03-03 HR HRP20201791TT patent/HRP20201791T1/hr unknown
- 2016-03-03 RS RS20201349A patent/RS61047B1/sr unknown
- 2016-03-03 JP JP2017546702A patent/JP6811718B2/ja active Active
- 2016-03-03 EP EP20181578.4A patent/EP3741855A1/en active Pending
- 2016-03-03 CA CA2978632A patent/CA2978632C/en active Active
- 2016-03-03 CN CN201680026012.9A patent/CN107847553A/zh active Pending
- 2016-03-03 EP EP16710890.1A patent/EP3265565B1/en active Active
- 2016-03-03 KR KR1020177028574A patent/KR102697493B1/ko active Active
- 2016-03-03 IL IL284264A patent/IL284264B/en unknown
- 2016-03-03 MX MX2017011298A patent/MX379585B/es unknown
-
2017
- 2017-09-03 IL IL254271A patent/IL254271B/en unknown
- 2017-09-26 ZA ZA2017/06459A patent/ZA201706459B/en unknown
-
2019
- 2019-11-01 US US16/671,376 patent/US11479774B2/en active Active
-
2020
- 2020-10-28 JP JP2020180195A patent/JP7090933B2/ja active Active
- 2020-11-10 CY CY20201101053T patent/CY1123489T1/el unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Brueckl et al. | Clinically relevant prognostic and predictive markers for immune-checkpoint-inhibitor (ICI) therapy in non-small cell lung cancer (NSCLC) | |
| JP2018508532A5 (enExample) | ||
| Banin Hirata et al. | Molecular markers for breast cancer: prediction on tumor behavior | |
| Mai et al. | PIWI-interacting RNA-54265 is oncogenic and a potential therapeutic target in colorectal adenocarcinoma | |
| Hwang | Overcoming docetaxel resistance in prostate cancer: a perspective review | |
| Shen et al. | TGF-β regulates hepatocellular carcinoma progression by inducing Treg cell polarization | |
| Saurer et al. | TREM-1 promotes intestinal tumorigenesis | |
| JP7032329B2 (ja) | ｃ－ＭＡＦの状態に基づく乳がんの治療的処置 | |
| RU2017134347A (ru) | Способы лечения рака, имеющего гемизиготную потерю тр53 | |
| Giuliano et al. | Resistance to lysosomotropic drugs used to treat kidney and breast cancers involves autophagy and inflammation and converges in inducing CXCL5 | |
| Jiang et al. | Efficacy and safety of sintilimab in combination with chemotherapy in previously untreated advanced or metastatic nonsquamous or squamous NSCLC: two cohorts of an open-label, phase 1b study | |
| US20140030257A1 (en) | Agtr1 as a marker for bevacizumab combination therapies | |
| Miyoshi et al. | Close correlation between CXCR4 and VEGF expression and frequent CXCR7 expression in rhabdomyosarcoma | |
| Wubetu et al. | High STAT4 expression is a better prognostic indicator in patients with hepatocellular carcinoma after hepatectomy | |
| Löb et al. | Prognostic effect of HER2 evolution from primary breast cancer to breast cancer metastases | |
| Marmé et al. | CD24 Ala57Val polymorphism predicts pathologic complete response to sequential anthracycline-and taxane-based neoadjuvant chemotherapy for primary breast cancer | |
| Lou et al. | Relationship between PD-L1 expression and clinical characteristics in patients with breast invasive ductal carcinoma | |
| Lundy et al. | TLR2 activation promotes tumour growth and associates with patient survival and chemotherapy response in pancreatic ductal adenocarcinoma | |
| Zhuo et al. | TAGLN2 induces resistance signature ISGs by activating AKT-YBX1 signal with dual pathways and mediates the IFN-related DNA damage resistance in gastric cancer | |
| Scholfield et al. | Defining the genomic landscape of diffuse sclerosing papillary thyroid carcinoma: prognostic implications of RET fusions | |
| Liu et al. | Overexpression of POLA2 in hepatocellular carcinoma is involved in immune infiltration and predicts a poor prognosis | |
| ES2817331T3 (es) | Uso del cabazitaxel en el tratamiento del cáncer de próstata | |
| Kumazawa et al. | Expression of non‑homologous end joining factor, Ku80, is negatively correlated with PD‑L1 expression in cancer cells after X‑ray irradiation | |
| Choi et al. | Mapping immunotherapy potential: spatial transcriptomics in the unraveling of tumor-immune microenvironments in head and neck squamous cell carcinoma | |
| Gao et al. | Low SLC29A1 expression is associated with poor prognosis in patients with hepatocellular carcinoma |